- Policy
- Domestic vaccine development for COVID-19 aims at 2021
- by Lee, Jeong-Hwan Jul 17, 2020 05:55am
- It is expected that the government will start a clinical trial of COVID-19 blood plasma therapy in early September and will be able to secure treatments throughout the year. Antibody therapies, except for blood plasma therapies, are scheduled to go through clinical trials, and the government expects that antibody therapies will be secured
- Company
- 2nd single-agent immunotherapy added for NSCLC first-line
- by Eo, Yun-Ho Jul 16, 2020 05:55am
- Another immunotherapy is expected to be added as a first-line treatment option in lung cancer. The pharmaceutical industry sources reported, Roche Korea has recently submitted an application to Korea’s Ministry of Food and Drug Safety (MFDS) to indicate programmed death-ligand 1 (PD-L1) inhibiting immunotherapy Tecentriq (atezolizumab)
- Policy
- The MFDS will enact a law covering special cases
- by Lee, Tak-Sun Jul 16, 2020 05:54am
- The MFDS decided to promote the establishment of a law covering special cases to support the approval of vaccines and treatments for new infectious diseases such as COVID-19. It also plans to establish the Central IRB to expedite clinical trials. The MFDS made the announcement through the 'Major Business Reports' submitted to the National
- Company
- Influenza vaccine inoculation rate doubled from last year
- by Jul 16, 2020 05:54am
- n the aftermath of COVID-19, the number of influenza vaccination in the National Essential Immunization Vaccine (NIP) increased significantly in the first half of this year. On the other hand, for the same reason, other essential vaccination rates are rather have declined. According to the KCDC on the 13th, the number of NIP inoculations from
- Opinion
- [Reporter’s Note] Hasty move on anti-droplet masks
- by Jul 16, 2020 05:54am
- “Anti-droplet masks? They’ll be available from Monday. People with waiting number tickets given out from 9:30 in the morning can buy a box each.” This is the answer I got at a hypermarket in Seoul asking for an anti-droplet mask. The anti-droplet mask has been in the hypermarkets and convenient stores for a month now, but they are a ra
- Policy
- Use patent of Xarelto 2.5mg listed late
- by Lee, Tak-Sun Jul 15, 2020 07:54am
- Although Hanmi and SK Chemicals acquired market monopoly rights as a follow-up drug to the anticoagulant drug (NOAC), Xarelto 2.5mg (Rivaroxaban), it may not exercise its right. This is because the use patent for Xarelto 2.5mg has been listed in the MFDS after the acquisition of the rights of both companies. According to the MFDS, H
- Company
- "Ezetimibe combination drug, now key option in dyslipidemia"
- by Eo, Yun-Ho Jul 15, 2020 06:33am
- Statin has been demonstrating outstanding efficacy in low-density lipoprotein cholesterol (LDL-C) level control, while showing an assuring benefit in risk of cardiovascular death. The medicine has surely shifted the paradigm of dyslipidemia management. Nevertheless, there is no perfect drug in this world. Statin also has concerning repor
- Product
- Will electronic masks by LG be commercialized?
- by Kang, Shin-Kook Jul 15, 2020 06:33am
- Electronic masks made by famous domestic home appliance companies are attracting attention. LG Electronics announced on the 12th that it has donated 2000 electronic masks made of electronics and IT technology to Severance Hospital to express appreciation and support to medical staff who need to work while wearing masks to overcome COVID-19.
- Company
- Zepzelca by Boryung designated as an orphan Drug
- by An, Kyung-Jin Jul 15, 2020 06:33am
- Boryung announced on the 13th that it is in the process of receiving a new drug called small-cell lung cancer (SCLC) 'Zepzelca' (Lurbinectedin) as an orphan drug. Zepzelca is an anticancer drug that Boryung has exclusive rights to domestic development and sales. In 2017, Boryung signed a technology introduction contract with PharmaMar in S
- Policy
- Emergency use of KRW 5.13 mln Soliris covered for aHUS
- by Lee, Hye-Kyung Jul 15, 2020 06:32am
- Soliris (eculizumab) injection costing 5.13 million won per vial is to get coverage for an emergency administration. Korea’s Health Insurance Review and Assessment Service (HIRA) has recently made an additional checkbox on the preliminary approval application for Soliris. The government body issued a notice on July 10 stating an eme
